Interobserver agreement in scoring immunohistochemical overexpression of Her2 detected by five different antibodies on tissue microarrays of breast carcinomas;Concordância interobservador na interpretação imuno-histoquímica da superexpressão do Her2 detectada por cinco diferentes anticorpos em array de carcinomas mamários

Jornal Brasileiro de Patologia e Medicina Laboratorial

Volumn 43, Issue 5, 2007, Pages 373-379

  Nunes, Cristiana Buzelin ^a   Rocha, Rafael Malagoli ^b   Gouvêa, Agostinho Pinto ^b,c   Tafuri, Luciene Simões De Assis ^b,d   Marinho, Vanessa Fortes Zschaber ^b   Rezende, Marina Alvarenga ^e   Gobbi, Helenice ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UFMG   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d Graduation in Information Systems and Knowledge Management   (Brazil)

^e Interdisciplinar Center for Research and Assistance on Aging   (Brazil)

Author keywords

Breast cancer; Her2; Immunohistochemical; Interobserver agreement

Indexed keywords

EID: 37349066329     PISSN: 16762444     EISSN: 16784774     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. BANKFALVI, A. et al. Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. Histopathology, v. 37, n. 5, p. 411-9, 2000.
2. BILOUS, M. et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol, v. 16, n. 2, p. 173-82, 2003.
3. DAKO HERCEPTEST™. A manual for interpretation. Carpinteria, 1999.
4. DANDACHI, N.; DIETZE, O.; HAUSER-KRONBERGER, C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest, v. 82, n. 8, p. 1007-14, 2002.
5. ELLIS, I. O. et al. Best Practice No 176: updated recommendations for HER2 testing in the UK. J Clin Pathol, v. 57, n. 3, p. 233-7, 2004.
6. FITZGIBBONS, P. L. et al. Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey. Arch Pathol Lab Med, v. 130, n. 10, p. 1440-5, 2006.
7. GOUVEA, A. P. et al. Her-2/neu immunoreactivity in invasive mammary carcinomas: a comparative study using monoclonal and polyclonal antibodies including the Herceptest. J Bras Patol Med Lab, v. 40, n. 1, p. 47-52, 2004.
8. GOUVEA, A. P. et al. Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas. Appl Immunohistochem Mol Morphol, v. 14, n. 1, p. 103-8, 2006.
9. HANNA, W.; KAHN, H. J.; TRUDEAU, M. Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside. Mod Pathol, v. 2, n. 8, p. 827-34, 1999.
10. HOANG, M. P.et al. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol, v. 113, n. 6, p. 852-9, 2000.
11. LACROIX-TRIKI, M. et al. High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: A multicentre GEFPICS study. Eur J Cancer, v. 42, n. 17, p. 2946-53, 2006.
12. LANDIS, J. R.; KOCH, G. G. The measurement of observer agreement for categorical data. Biometrics, v. 33, n. 1, p. 159-74, 1977.
13. MILES, D. W. Update on HER-2 as a target for cancer therapy: herceptin in the clinical setting. Breast Cancer Res, v. 3, n. 6, p. 380-4, 2001.
14. Paik, S. et al. Real-world performance of HER2 testing: National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst, v. 94, n. 11, p. 852-4, 2002.
15. PEREZ, E. A. et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol, v. 24, n. 19, p. 3032-8, 2006.
16. PICCART, M. J.; DI LEO A.; HAMILTON, A. HER2. a "predictive factor" ready to use in the daily management of breast cancer patients? Eur J Cancer, v. 36, n. 14, p. 1755-61, 2000.
17. PRESS, M. F. et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol, v. 20, n. 14, p. 3095-105, 2002.
18. ROCHA, R. M. et al. Construção de arrays de tecido com equipamento alternativo e de baixo custo para estudo imunoistoquímico de tumores mamários. J Bras Patol Med Lab, v. 42, n. 6, p. 477-82, 2006.
19. ROSS, J. S.; FLETCHER, J. A. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol, v. 112, n. 1, suppl 1, p. S53-67, 1999.
20. ROSSI, S. et al. Rabbit monoclonal antibodies: a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies. Am J Clin Pathol, v. 124, n. 2, p.2 95-302, 2005.
21. SALES, A. O.; RODRIGUES, S. J. P.; BACCHI, C. E. Estudo comparativo entre os métodos LSAB®+ e Herceptest® para a detecção de HER-2/neu em carcinoma de mama. J Bras Patol Med Lab, v. 40, n. 4, p. 265-71, 2004.
22. SAMPATANUKUL, P. et al. A two-phase study model for the standardization of HER2 immunohistochemical assay on invasive ductal carcinoma of the breast. J Med Assoc Thai, v. 88, n. 11, p. 1680-8, 2005.
23. SCHNITT, S. J. Breast cancer in the 21st century: neu opportunities and neu challenges. Mod Pathol, v. 14, n. 3, p. 213-8, 2001.
24. SLAMON, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, v. 235, n. 4785, p. 177-82, 1987.
25. THOMSON, T. A. et al. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol, v. 14, n. 11, p. 1079-86, 2001.
26. TSUDA, H. et al. Concordance in judgments among cerbB-2 (HER2/neu) overexpression detected by two immunohistochemical tests and gene amplification detected by Southern blot hybridization in breast carcinoma. Pathol Int, v. 51, n. 1, p. 26-32, 2001.
27. TSUDA, H. et al. Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2/neu (c-erbB-2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and TAB250 in breast carcinoma. Pathol Int, v. 52, n. 2, p. 126-34, 2002.
28. VINCENT-SALOMON, A. et al. Re: HER2 testing in the real world. J Natl Cancer Inst, v. 95, n. 8, p. 628; author reply p. 628-9, 2003.
29. WOLFF, A. C. et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol, v. 25, n. 1, p. 118-45, 2006.